ABSTRACT

Introduction

As one of the most efficacious methods of cancer immunotherapy, chimeric antigen receptor-modified immune cells have recently drawn enormous attention. After the great success achieved with CAR-T-cells in cancer treatment both in preclinical setting and in the clinic, other types of immune cells, including natural killer (NK)-cells and macrophages, have been evaluated for their anti-cancer effects along with their potential superiority against CAR-T-cells, especially in terms of safety. First introduced by Tran et al. almost 26 years ago, CAR-NK-cells are now being considered as efficient immunotherapeutic modalities in various types of cancers, not only in preclinical setting but also in numerous phase I and II clinical studies.

Areas Covered

In this review, we aim to provide a comprehensive survey of the preclinical studies on CAR-NK-cells’ development, with an evolutional approach on CAR structures and their associated signaling moieties. Current NK-cell sources and modes of gene transfer are also reviewed.

Expert Opinion

CAR-NK-cells have appeared as safe and effective immunotherapeutic tools in preclinical settings; however, designing CAR structures with an eye on their specific biology, along with choosing the optimal cell source and gene transfer method require further investigation to support clinical studies.

中文翻译：

---

嵌合抗原受体修饰的自然杀伤细胞在癌症免疫治疗中的临床前研究：综述

摘要

介绍

作为最有效的癌症免疫治疗方法之一，嵌合抗原受体修饰的免疫细胞最近引起了极大的关注。在 CAR-T 细胞在临床前和临床中的癌症治疗中取得巨大成功之后，其他类型的免疫细胞，包括自然杀伤 (NK) 细胞和巨噬细胞，也被评估了它们的抗癌作用。与 CAR-T 细胞相比具有潜在优势，尤其是在安全性方面。由Tran 等人首先介绍。大约 26 年前，CAR-NK 细胞现在被认为是各种癌症的有效免疫治疗方式，不仅在临床前环境中，而且在众多 I 期和 II 期临床研究中。

涵盖的领域

在这篇综述中，我们的目标是对 CAR-NK 细胞发育的临床前研究进行全面调查，并提供关于 CAR 结构及其相关信号部分的进化方法。还回顾了当前的 NK 细胞来源和基因转移模式。

专家意见

CAR-NK 细胞已在临床前环境中作为安全有效的免疫治疗工具出现；然而，设计 CAR 结构时着眼于其特定的生物学，以及选择最佳的细胞来源和基因转移方法，需要进一步调查以支持临床研究。